# Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
Canonical URL: https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-report-fourth-quarter-and-year-end-2025-financial-resu-d112b464
Ticker: ABOS
Company: Acumen Pharmaceuticals
Source: Acumen Pharmaceuticals
Published: 2026-03-19 20:00 EST
## Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage...

## Article Body
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2025 financial results on Thursday, March 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

The webcast audio will be available via this link.

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com .

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE ® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com .

Investors: Alex Braun abraun@acumenpharm.com

Media:

ICR Healthcare AcumenPR@icrhealthcare.com
## Recent Company News
- 2026-07-15 11:30 EST — [Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-highlights-enhanced-brain-delivery-ebd-program-data-and-e-12dd8779) — Source: Acumen Pharmaceuticals
- 2026-07-07 11:30 EST — [Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-present-data-on-enhanced-brain-delivery-ebd-technology-95eca401) — Source: Acumen Pharmaceuticals
- 2026-06-16 11:30 EST — [Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-announces-nomination-of-two-enhanced-brain-delivery-ebd-d-d74b8122) — Source: Acumen Pharmaceuticals
- 2026-05-12 11:00 EST — [Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-ba885971) — Source: Acumen Pharmaceuticals
- 2026-05-07 20:00 EST — [Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference](https://biopharmsignal.com/news/ABOS/acumen-pharmaceuticals-to-participate-in-the-bank-of-america-securities-2026-hea-e907fb55) — Source: Acumen Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)